Media Contact:

    Pam Lord
    Canale Communications
    619-849-6003
    plord@canalecomm.com

NPI-2358 Published Manuscripts

1) New Aspects of Potent Anti-Microtubule Agents Phenylahistin and Tubulin Photoaffinity Labeling; Y Hayashi, Y Yamazaki, K Kohno, A Oda, K Tanaka, STC Neuteboom, AM Barral, B Nicholson, B Potts, GK Lloyd, Y Kiso: Proceedings of 43JPS/PEM4, Hitoshi Ishida and Hisakazu Mihara (Editors), Japanese Peptide Society, 2006

2) NPI-2358 is a Tubulin-depolymerizing Agent: In-vitro Evidence for Activity as a Tumor Vascular-disrupting Agent; B Nicholson, GK Lloyd, BR Miller, MA Palladino, Y Kiso, Y Hayashi, STC Neuteboom: Anti-Cancer Drugs 2006, 17:25-31A

3) Convenient Synthetic Method for Monodehydro-2,5-diketopiperazines; Y Hayashi, A Oda, Y Yamazaki, Y Okuno, Y Kiso: Understanding Biology Using Peptides. Sylvie Blondell (editor), American Peptide Society, 2005

NPI-2358 Published Abstracts and Posters

1) Phase 1 Trial of NPI-2358 (a novel vascular disrupting agent) Plus Docetaxel;
M. Millward, A. Mita, M.A. Spear, K.C. Federico, G.K. Lloyd, G. Cropp, M. Mita, P. Mainwaring: J Clin Oncology, 2009 ASCO Annual Meeting (Post-Meeting Edition), Vol 27, No 15s (May 20 supp, abstr 3571), 2009

2) Phase I Study of NPI-2358 (a novel vascular disrupting agent) in Patients with Solid Tumors and Lymphomas; A.C. Mita, L.K. Yee, K.P. Papadopoulos, E.I. Heath, O. Romero, G.K. Lloyd, G. Cropp, M.A. Spear, M.M. Mita, P.M. LoRusso. Journal of Clin Oncology 26: 2008 (May 20 suppl; abstr 3525)

3) A Phase 1 Dynamic Accelerated Titration Dose Escalation Study of the Vascular Disrupting Agent NPI-2358; M.A. Spear, P LoRusso, A.W. Tolcher, C. Lin, D. Want, E. Heath, G.K. Lloyd, G Cropp, K.P. Papdopoulos. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part 1. Vol 25, No. 18s (June Supplement), 2007: 14097

4) A Phase I Accelerated Titration Dose Escalation Study of the Vascular Disrupting Agent NPI-2358 Utilizing DCE-MRI; Patricia LoRusso, Kyri Papadopoulos, Anthony Tolcher, Chia-Chi Lin, K Lloyd, E Morgan, Edward Ashton, Gillian Cropp, M Spear: AACR 2007

5) NPI-2358, A Novel Tumor Vascular Disrupting Agent: Summary of Preclinical Profile and Ongoing Phase 1 Clinical Trial; GK Lloyd, S Neuteboom, M Spear: 10th International Workshop on the Tumor Microenvironment, 2006

6) Synopsis of NPI-2358 - A Tumor Vascular Disrupting Agent with Additional Direct Antitumor Activity; G K Lloyd: 4th Annual Angiogenesis and Vascular Targeting Agents, Drug Discovery & Development, 2006

7) Development of Vascular Disrupting Agents Based on Anti-microtubule Diketopiperazine – Synthesis of a Photoaffinity Probe for Tubulin Recognition; Y Hayashi, Y Yamazaki, K Kohno, Y Kiso, S Neuteboom, AM Barral, B Potts, GK Lloyd: Japanese Medicinal Chemistry Symposium, 2006

8) Medicinal Chemistry, Chemical Biology and Chemical Pharmaceutics of New Microtubule Targeting Agents; Y Hayashi, Y Yamazaki, Y Kiso, K Kohno, K Takayama, T Fujita, A Yamamoto, S Neuteboom, AM Barral, B Nicholson, B Potts, GK Lloyd: 2nd International Conference on Biomolecules and Related Compounds, 2006

9) NPI-2358, a Novel Tumor Vascular Disrupting Agent; B Nicholson, J Bishop, Y Hayashi, MA Jordan, L Wilson, Y Kiso, P Borgstrom, MA Palladino, STC Neuteboom, GK Lloyd: AACR Annual Meeting, 2005

10) Preclinical Profile of NPI-2358, a Tumor Vascular Disrupting Agent; GK Lloyd, L Wilson, J Bishop, B Nicholson, M Palladino, P Borgstrom, DJ Honess, GM Tozer, D Siemann, G Mangold, Y Kiso, STC Neuteboom, Y Hayashi: AACR-NCI-EORTC Meeting, 2005

11) NPI-2358, A Novel Diketopiperazine Vascular Disrupting Agent (VDA) with Potent Anti-tumor Activity; GK Lloyd, Y Hayashi, D Siemann, L Wilson, J Bishop, P Borgstrom, G Mangold, B Nicholson, STC Neuteboom, MA Palladino: 9th International Workshop on the Tumor Microenvironment, 2005

12) The Anti-proliferative Mechanism of Action of Novel Microtubule-targeted Phenylahistins NPI-2350 and NPI-2358 as compared with Colchicine; J Bishop, B Nicholson, GK Lloyd, MA Jordan, L Wilson: AACR-NCI-EORTC Meeting, 2005

13) The Efficacy of the Novel Diketopiperazine NPI-2358 as an Antivascular Agent is Confirmed in the P22 Rat Tumor System; DJ Honess, F Hylands, GK Lloyd, GM Tozer: 9th International Workshop on the Tumor Microenvironment, 2005


Posters (2005-2008)

14) NPI-2358 (A Novel Vascular Disrupting Agent) A Phase 1 Study with RP2D Cohort in Patients with Solid Tumors and Lymphomas; A Mita, MA Spear, L Yea, P Papadopoulos, EI Heath, MJ Pilat, O Romero, GK Lloyd, K Federico, E Ashton, G Cropp, M Mita, P LoRusso: ASCO Meeting, 2008

15) Development of Potent Anti-Microtubule Agents Abased on Natual Diketopiperazine Phenylahistin and Tubulin Photoafficnity labeling; Y Hayashi, Y Yamazaki, STC Neuteboom, AM Barral, B Potts, GK Lloyd, Y Kiso: IUPAc Conference on Biodiversity and Natural Products, 2006

16) Preclinical Profile of NPI-2358, a Tumor Vascular Disrupting Agent; GK Lloyd, L Wilson, J Bishop, B Nicholson, M Palladino, P Borgstrom, DJ Honess, GM Tozer, D Siemann, G Mangold, Y Kiso, STC Neuteboom, Y Hayashi: AACR-NCI-EORTC Meeting, 2005

17) NPI-2358, a Novel Tumor Vascular Disrupting Agent; B Nicholson, J Bishop, Y Hayashi, MA Jordan, L Wilson, Y Kiso, P Borgstrom, MA Palladino, STC Neuteboom, GK Lloyd: AACR Annual Meeting, 2005


 

###

Nereus Pharmaceuticals is a registered trademark of Nereus Pharmaceuticals, Inc. All other product and company names may be registered trademark or trademarks of their respective owners.